Synonym
Zabofloxacin D-aspartate; A0QFV40KA8; UNII-A0QFV40KA8; 1808295-63-7
IUPAC/Chemical Name
D-aspartic acid--(Z)-1-cyclopropyl-6-fluoro-7-(8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (1/1)
InChi Key
OBWXDHHUYKIHDV-USSIZITKSA-N
InChi Code
InChI=1S/C19H20FN5O4.C4H7NO4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17;5-2(4(8)9)1-3(6)7/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28);2H,1,5H2,(H,6,7)(H,8,9)/b23-14+;/t;2-/m.1/s1
SMILES Code
N[C@H](CC(O)=O)C(O)=O.CO\N=C1/CN(CC12CNC2)C3=C(F)C=C4C(=O)C(=CN(C5CC5)C4=N3)C(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
534.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kocsis B, Gulyás D, Szabó D. Delafloxacin, Finafloxacin, and Zabofloxacin:
Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics (Basel). 2021 Dec
8;10(12):1506. doi: 10.3390/antibiotics10121506. PMID: 34943718; PMCID:
PMC8698389.
2: Kocsis B, Szabo D. Zabofloxacin for chronic bronchitis. Drugs Today (Barc).
2016 Sep;52(9):495-500. doi: 10.1358/dot.2016.52.9.2530595. PMID: 27883116.
3: Park HS, Oh SH, Kim HS, Choi DR, Kwak JH. Antimicrobial Activity of
Zabofloxacin against Clinically Isolated Streptococcus pneumoniae. Molecules.
2016 Nov 17;21(11):1562. doi: 10.3390/molecules21111562. PMID: 27869677; PMCID:
PMC6273590.
4: Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of
novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin,
zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016 May
23;15(1):34. doi: 10.1186/s12941-016-0150-4. PMID: 27215369; PMCID: PMC4878067.
5: Rhee CK, Chang JH, Choi EG, Kim HK, Kwon YS, Kyung SY, Lee JH, Park MJ, Yoo
KH, Oh YM. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation:
a multicenter, double-blind, double-dummy, randomized, controlled, Phase III,
non-inferiority trial. Int J Chron Obstruct Pulmon Dis. 2015 Oct 22;10:2265-75.
doi: 10.2147/COPD.S90948. PMID: 26543359; PMCID: PMC4622522.
6: Jin HE, Lee KR, Kang IH, Chung SJ, Shim CK. Determination of zabofloxacin in
rat plasma by liquid chromatography with mass spectrometry and its application
to pharmacokinetic study. J Pharm Biomed Anal. 2011 Mar 25;54(4):873-7. doi:
10.1016/j.jpba.2010.11.001. Epub 2010 Nov 9. PMID: 21112170.
7: Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA. Zabofloxacin (DW-224a)
activity against Neisseria gonorrhoeae including quinolone-resistant strains.
Diagn Microbiol Infect Dis. 2008 Sep;62(1):110-2. doi:
10.1016/j.diagmicrobio.2008.05.010. Epub 2008 Jul 11. PMID: 18620833.
